LMR Partners’s Aevi Genomic Medicine Inc GNMX Stock Holding History

LMR Partners’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-112,265	Closed	-$149K	–	634
2017 Q2	$149K	Buy	+112,265	New	+$162K	0.01%	550

Other funds holding GNMX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

NCMW

Northern Capital Management (Wisconsin) Madison, Wisconsin $373M AUM 11.01% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

LMR Partners's GNMX Position: Q3 2017 in Review

LMR Partners sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2017, closing a stake of 112,265 shares — an estimated $149K sold.

LMR Partners first reported a position in GNMX in Q2 2017 and held it in 1 quarter. The position peaked at $149K in Q2 2017. 49 funds tracked by Wall St. Rank hold GNMX as of Q3 2017.

LMR Partners reported no remaining Aevi Genomic Medicine Inc position as of Q3 2017 after selling out during the quarter.
LMR Partners sold 112,265 Aevi Genomic Medicine Inc shares in Q3 2017, an estimated $149K.
LMR Partners first reported a position in Aevi Genomic Medicine Inc in Q2 2017 and held it in 1 quarter.
LMR Partners's Aevi Genomic Medicine Inc position peaked at $149K in Q2 2017.
49 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.